Beyond Cancer

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a biopharmaceutical and medical device company in the development stage that utilizes ultra-high concentration nitric oxide (UNO) via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Ultra-high concentrations of nitric oxide have demonstrated anti-cancer properties and have the potential to act as a chemosensitizer and radiotherapy enhancer. A first-in-human study targeting solid tumor patients is currently underway. The company is conducting preclinical studies of UNO across various solid tumor models to provide additional therapeutic options.